Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ACTIVE NOT RECRUITING
NCT03554174
PHASE1
Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder
Sponsor: Yale University
View on ClinicalTrials.gov
Summary
The primary goal of this pilot study is to investigate whether psilocybin alters neuroplasticity in people with major depressive disorder. The primary hypothesis is that psilocybin will result in neuroplastic changes that parallel improvement in symptoms of depression.
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
18
Start Date
2018-02-27
Completion Date
2026-09
Last Updated
2025-11-05
Healthy Volunteers
No
Conditions
Interventions
DRUG
Low Dose Psilocybin
0.1 mg/kg psilocybin capsule
DRUG
Placebo
microcrystalline cellulose capsule
DRUG
Medium Dose Psilocybin
0.3 mg/kg psilocybin capsule
Locations (1)
VA Connecticut Healthcare System, West Haven Campus
West Haven, Connecticut, United States